Nanexa logo

Nanexa Investor Relations Material

Nanexa AB focuses on developing nanoparticle technology for drug delivery. The company utilizes their proprietary NxCore platform to transform drugs from conventional to nanomedicines. Their lead product candidate is Nanoxel, a nanomedicine that targets oral mucositis, a common and exceptionally debilitating side effect in cancer patients receiving chemotherapy and radiation therapies; and angina pectoris and heart failure caused by atherosclerosis, a build-up of plaque in the blood vessels. The company intends to transform new products into nanomedicines or develop completely new nanomedicines.

Upcoming events for

Q2 20222022-07-21

Latest company events

More about Nanexa

Ticker symbol

NANEXA

Country

Sweden

Dig deeper into the Nanexa fundamentals on Quartr.

  • Skip straight to the Q&A session
  • Receive notifications about new events
  • Connect the financial calender on your phone
  • Figure out why the stock is up or down
  • Read the transcripts or scroll the deck
  • Access earnings or press releases
App store link
Android play link
Quartr app screenshot